NDRA logo

ENDRA LIFE SCIENCES INC

NDRANASDAQ
πŸ† #5051 by market capUS Equity
$5.76β–Ό $0.16 (βˆ’2.70%)
After hours Β· at close
πŸ””
Track NDRA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.7%
7dβ–Ό 6.2%
14dβ–² 2.9%
30dβ–² 11.7%
ytdβ–² 23.3%
1yβ–² 3.4%
🏦Market Cap
$12M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
51.4%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
23.3x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$5.72 – $5.84
52-Week Range
$2.96 – $9.85
Volume
$4.08B
Avg Volume
$3.88B
Shares Outstanding
2.1M
Next Earnings
Oct 22, 2026

Fundamentals Snapshot

Annual Revenue
$373,867
Last Q Revenue
$93,282
P/E Ratio
β€”
P/S Ratio
23.3x
EPS (TTM)
$-5.98
Dividend Yield
β€”

Why Investors Own NDRA

  • βœ“High-growth profile β€” revenue up +17.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 30% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NDRA logo

ENDRA LIFE SCIENCES INC

NDRA
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$373,867β–² +16.1% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.6%β–² +3.9% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$93,841β–² +16.1% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$21,310β–² +16.1% YoY
StockOtter Β· stockotter.space

About ENDRA LIFE SCIENCES INC

ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$6.34
β–² +10.2% Upside
High Target$7.73
Low Target$5.48
Based on 34 analysts

Latest News & Updates